Replies to post #318816 on Anavex Life Sciences Corp (AVXL)

[plexrec]

Granite-TREATMENT OF GENETIC NEURODEVELOPMENTA--European patent--do you have a link for this ? showing specifics ??? Thanks

[tradeherpete]

Wow, Graniteguy.

I haven’t seen that.

[falconer66a]

More undisclosed Anavex info.

From the European Patent Office: ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERS

Stunning. Makes no sense. Those of us who know a bit of the molecular mechanics of the referenced aneuploid genetic diseases want to know how Anavex sigma-1 receptor activators could possibly resolve the profound problems caused by anomalous numbers of chromosomes. Fixing dysfunctional homeostatic processes in nerves, by way of sigma-1 receptor activation, is one thing. Makes sense. Fixing, treating the neurodevelopment problems caused by aneuploidy, anomalous numbers of chromosomes, raises a host of questions.

Down's syndrome is mentioned. The condition is Trisomy-21, with an extra 21st chromosome. Normally, there is but a pair, one from each parent. With three, also sorts of development anomalies occur, the typical Down's syndrome symptoms. I'd sure like to understand how the Anavex molecules might help treat this condition. Can't see how it could disable or remove the complicating superfluous chromosome.

A mystery, for me, altogether. But I'm not concerned. Anavex isn't arbitrarily making up these things. I've perceived from the start that Anavex has behind their closed lab doors a multitude of trade-secret data on what diseases and conditions their drugs can favorably impact. There will be far more to the Anavex story than just sigma-1 receptor activation in neurons. Revelations of such in coming months and years are going to be astounding.

[RedShoulder]

From the European Patent Office: ANAVEX2-73 FOR THE TREATMENT OF GENETIC NEURODEVELOPMENTAL DISORDERS:

The first group, known as the Aneuploidy group, comprises disorders caused by an abnormal number of chromosomes. The primary example in this group is Down’s syndrome.



The second group consists of disorders chromosomal micro-deletions, such as the deletion of a chromosomal region. Examples in this group are William’s Beuren syndrome, Prader-Willi syndrome, Angelman syndrome, Smith-Magenis syndrome, and velo-cardio-facial syndrome.



The third group consists of disorders having a single gene defect. Examples in this group are ATR-X syndrome, Barth syndrome, Fragile X- syndrome, ICF syndrome, Neurofibromatosis, Rett syndrome, and Smith-Lemli-Opitz syndrome.



The last group is believed to be caused by a combination of genetic, environmental, and epigenetic factors. Examples in this group are addictive disorders, ADHD, anxiety disorders, Asperger’s syndrome, autistic disorders, depression, dyslexia, eating disorders, epilepsy, infantile spasms, fetal alcohol syndrome, hydrocephalus, manic depressive illness, mental retardation, schizophrenia, spina bifida, and Tourette’s syndrome.

Thanks Granite for this very informative post.

In the second group Anavex has Angelman Syndrome to be treated with A2-73 in the pipeline.

In the third group Anavex has Rett Syndrome and Fragile X both treated with A2-73 in the pipeline.

In the fourth group Anavex has Depression to be treated with A1-41 and Infantile Spasms to be treated with A2-73 in the pipeline.

Now the question is how many of these other rare 'Genetic Neurodevelopmental Disorders' can be treated with various drugs in the Anavex drug portfolio? I suspect more than a few.